Trulieve Cannabis is trading at $8.93 (+5.81%) in pre-market following a Q2 2026 earnings preview that drew investor focus to the upcoming August 07 report and the potential Schedule III transition.
- The pre-market move appears driven by investor positioning ahead of the results, with consensus estimates pointing to $284.08 million in revenue and an EPS of $0.06.
- The jump is largely company-specific rather than market-wide, as no separate overnight announcements were provided, shifting the focus toward the company's fundamental outlook and regulatory tailwinds.